Results 31 to 40 of about 34,322 (240)

Adalimumab: A key element in the treatment strategy for immune-mediated inflammatory diseases: A review [PDF]

Consilium Medicum
Adalimumab is a biological drug effectively used in the treatment of several immune-mediated inflammatory diseases, including ankylosing spondylitis, juvenile idiopathic arthritis, and psoriasis.
Mariam A. Gilavian, Daria V. Trunova, Anastasia V. Ustinova, Anna M. Sukhanova   +3 more
doaj   +1 more source

The efficacy of adalimumab in treating patients with central multifocal choroiditis

American Journal of Ophthalmology Case Reports, 2020
Purpose: To evaluate the efficacy of adalimumab in patients with central multifocal choroiditis (cMFC) refractory to conventional corticosteroid-sparing immunomodulatory agents (IMT). Methods: Medical records were reviewed from all patients with cMFC and
Evianne L. de Groot, Jeannette Ossewaarde - van Norel, Lintje Ho, Ninette H. ten Dam - van Loon, Joke H. de Boer   +4 more
doaj   +1 more source

Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis

JAMA Dermatology
ImportanceIt is unclear whether concomitant methotrexate enhances the effectiveness and persistence of adalimumab for psoriasis. The recent OPTIMAP randomized clinical trial that tested adalimumab against adalimumab with methotrexate could not adequately answer this question due to underrecruitment.ObjectiveTo determine the effectiveness of using ...
Yiu, Zenas Z N, Smith, Catherine H, Laws, Philip, Hampton, Philip J, Griffiths, Christopher E M, Warren, Richard B   +5 more
openaire   +2 more sources

Real‐World Trends in Prenatal Antirheumatic Drug Utilization in Ontario, Canada: A Cross‐Sectional Time‐Series Analysis

Arthritis Care &Research, EarlyView.
Objective This study aimed to describe real‐world trends in preconception and prenatal use of antirheumatic drugs among pregnant individuals with rheumatic diseases in Ontario, Canada. Methods We conducted a time‐series analysis using repeated cross‐sectional data to examine annual patterns of disease‐modifying antirheumatic drug (DMARD) use among ...
Shenthuraan Tharmarajah, Swaleh Hussain, Sara J. T. Guilcher, Lisa M. McCarthy, Dharini Mahendira, Howard Berger, Mina Tadrous   +6 more
wiley   +1 more source

Short‐term response to biologic therapy in psoriatic arthritis (PsA) is not influenced by disease duration at initiation of therapy

Arthritis Care &Research, Accepted Article.
Objectives We aimed to determine whether the short‐term response to biologics in biologic‐naïve psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods PsA patients who started biologic therapy from the year 2000 to 2025 were included for analysis. Patients considered in the early treatment (ET)
Sung Min Cho, Shangyi Gao, Daniel Pereira, Richard J. Cook, Dafna D. Gladman   +4 more
wiley   +1 more source

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

Arthritis Research & Therapy, 2021
Background To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free adalimumab biosimilar CT-P17 to European Union-approved adalimumab (EU-adalimumab) in subjects with active rheumatoid arthritis (RA).
Jonathan Kay, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Slawomir Jeka, Agnieszka Zielinska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska-Wlodarczyk, Piotr A. Klimiuk, Sang Joon Lee, Yun Ju Bae, Go Eun Yang, Jae Kyoung Yoo, Daniel E. Furst, Edward Keystone   +17 more
doaj   +1 more source

Oral Prebiotic Polysaccharide Hydrogels Sustaining Colon Antibody Release Alleviate Inflammatory Bowel Disease

Advanced Science, EarlyView.
An orally administered prebiotic polysaccharide hydrogel (predaGel) based on inulin and alginate‐dopamine is stable in the stomach, adheres to the intestine, and degrades slowly in the colon. It enables site‐specific delivery of anti‐TNF‐α and anti‐IL‐12/23 antibodies, scavenges reactive oxygen species, and remodels gut microbiota, offering effective ...
Xinyi Dong, Huan He, Li Cao, Fenghua Meng, Zhiyuan Zhong   +4 more
wiley   +1 more source

Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases

Pediatric Rheumatology Online Journal
Background In pediatric rheumatic diseases (PRD), adalimumab is dosed using fixed weight-based bands irrespective of methotrexate co-treatment, disease activity (DA) or other factors that might influence adalimumab pharmacokinetics (PK).
Tatjana Welzel, Klervi Golhen, Andrew Atkinson, Verena Gotta, David Ternant, Jasmin B. Kuemmerle-Deschner, Christine Michler, Gilbert Koch, Johannes N. van den Anker, Marc Pfister, Andreas Woerner   +10 more
doaj   +1 more source

Long‐Term Outcomes After Stoma Creation in Crohn's Disease: A Retrospective Cohort Study of 422 Patients

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim Stoma creation is often required in Crohn's disease (CD), most commonly because of progressive anorectal disease. As stoma closure strongly influences long‐term quality of life and surgical decision‐making, this study evaluated the indications and long‐term outcomes of stoma creation in patients with CD.
Kentaro Nagano, Ryuichi Kuwahara, Yusuke Tomoo, Kurando Kusunoki, Yuki Horio, Kei Kimura, Kozo Kataoka, Masataka Ikeda, Motoi Uchino, Hiroki Ikeuchi   +9 more
wiley   +1 more source

Levels of antibodies to adalimumab in children with juvenile idiopathic arthritis at different stages of treatment

Zdorovʹe Rebenka, 2023
Background. Juvenile idiopathic arthritis (JIA) is one of the most common rheumatological diseases of childhood. The central place in the problem of JIA belongs to the question of treatment the timeliness and adequacy of which determine the disease ...
T.V. Marushko, O.Ye. Onufreiv, Yu.V. Marushko, O.B. German   +3 more
doaj   +1 more source